Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare blood cancer that develops in the plasma cells, which are ...

New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the ...

Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare type of blood cancer that forms in plasma cells, a white ...

Plasma cell leukemia (PCL) is a rare disease that may present de novoor secondary to plasma cell myeloma. Advanced disease and extramedullary involvement are common clinical features at presentation.

Black Americans have double the risk of developing multiple myeloma compared to white Americans and are diagnosed at younger ...

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...

The immunologic abnormality demonstrated in multiple myeloma is considered to be the result of abnormal function of the malignant plasma cells whereby deranged protein synthesis results in the ...

In this article, Cerba dives into CAR+ T-cell therapy, from patient treatment to solutions for minimal residual disease (MRD) ...

The most effective means of improving host defense in myeloma may be reduction of the number of neoplastic plasma cells and levels of anomalous globulins in the serum with chemotherapy.

A new editorial was published in Oncoscience’s Volume 12 on January 14, 2025, titled “Pomalidomide improved immune profiles ...